Plus Therapeutics, Inc

(NASDAQ:PSTV)

Latest On Plus Therapeutics, Inc (PSTV):

Date/Time Type Description Signal Details
2023-05-16 17:55 ESTNewsPlus Therapeutics regains Nasdaq minimum bid price complianceN/A
2023-04-21 00:34 ESTNewsPlus Therapeutics GAAP EPS of -$0.14 beats by $0.01N/A
2023-04-21 00:34 ESTNewsPlus Therapeutics, Inc. (PSTV) Q1 2023 Earnings Call TranscriptN/A
2023-04-20 01:50 ESTNewsPlus Therapeutics Q1 2023 Earnings PreviewN/A
2023-02-24 07:45 ESTNewsPlus Therapeutics, Inc. (PSTV) Q4 2022 Earnings Call TranscriptN/A
2023-02-23 18:41 ESTNewsPlus Therapeutics GAAP EPS of -$0.77 misses by $0.02, revenue of $0.22M misses by $0.5MN/A
2022-11-21 13:54 ESTNewsPlus stock rises as radiotherapy shows promise in ongoing brain cancer studiesN/A
2022-10-21 11:31 ESTNewsPlus Therapeutics, Inc. (PSTV) Q3 2022 Earnings Call TranscriptN/A
2022-10-21 11:31 ESTNewsPlus Therapeutics Q3 net loss widens Y/YN/A
2022-10-20 20:57 ESTNewsPlus Therapeutics GAAP EPS of -$0.19 beats by $0.02, revenue of $73KN/A
2022-10-20 05:19 ESTNewsPlus Therapeutics Q3 2022 Earnings PreviewN/A
2022-10-07 20:12 ESTNewsPlus Therapeutics jumps 18% as JonesTrading adds another Buy ratingN/A
2022-09-22 22:17 ESTNewsPlus Therapeutics finalizes $17.6M grant from Texas, to get initial funds by October endN/A
2022-09-19 10:32 ESTNewsPlus Therapeutics (PSTV) Investor Presentation- SlideshowN/A
2022-08-17 23:17 ESTNewsPlus Therapeutics stock soars ~74% after hours on $17.6M funding grant from TexasN/A
2022-08-15 20:27 ESTNewsPlus Therapeutics stock soars 59% as 186RNL shows promise in brain cancer trialsN/A
2022-07-22 03:05 ESTNewsPlus Therapeutics GAAP EPS of -$0.24 misses by $0.02N/A
2022-07-22 03:05 ESTNewsPlus Therapeutics, Inc. (PSTV) CEO Dr. Marc Hedrick on Q2 2022 Results - Earnings Call TranscriptN/A
2022-07-21 01:41 ESTNewsPlus Therapeutics Q2 2022 Earnings PreviewN/A
2022-06-23 00:46 ESTNewsPlus Therapeutics inks contract to use Biocept's test for use in cancer trialN/A
2022-05-03 19:30 ESTNewsPlus Therapeutics, Inc.'s (PSTV) CEO Marc Hedrick on Q1 2022 Results - Earnings Call TranscriptN/A
2022-04-21 23:52 ESTNewsPlus Therapeutics GAAP EPS of -$0.19 misses by $0.01N/A
2022-04-21 07:52 ESTNewsPlus Therapeutics Q1 2022 Earnings PreviewN/A
2022-04-05 13:12 ESTNewsPlus Therapeutics, Medidata partner for glioblastoma therapy trialN/A
2022-02-25 13:09 ESTNewsPlus Therapeutics, Inc. (PSTV) CEO Marc Hedrick on Q4 2021 Results - Earnings Call TranscriptN/A
2022-02-24 17:36 ESTNewsPlus Therapeutics GAAP EPS of -$1.11 misses by $0.01N/A
2022-02-24 00:45 ESTNewsPlus Therapeutics Q4 2021 Earnings PreviewN/A
2022-02-23 04:56 ESTNewsPlus Therapeutics, Medidata team up for synthetic control arm solution in trialN/A
2022-01-06 17:04 ESTNewsPlus Therapeutics in pact with University of Texas for cancer therapeuticsN/A
2022-01-04 17:14 ESTNewsPlus Therapeutics jumps 72% after achieving significant milestones for radiotherapeuticN/A
2021-12-22 02:47 ESTNewsPlus Therapeutics CEO Dr. Marc Hedrick - Cancer's Hardest ProblemsN/A
2021-11-18 21:27 ESTNewsPlus Therapeutics discloses interim data for Rhenium-186 NanoLiposome in glioblastomaN/A
2021-10-22 17:58 ESTNewsPlus Therapeutics EPS misses by $0.04N/A
2021-10-22 17:58 ESTNewsPlus Therapeutics, Inc. (PSTV) CEO Marc Hedrick on Q3 2021 Results - Earnings Call TranscriptN/A
2021-10-22 17:57 ESTNewsPlus Therapeutics shares fall after Q3 results, cash position updateN/A
2021-10-21 14:54 ESTNewsPlus Therapeutics Q3 2021 Earnings PreviewN/A
2021-10-19 16:43 ESTNewsPlus Therapeutics gets FDA greenlight for Rhenium-186 leptomeningeal metastases studyN/A
2021-09-03 01:01 ESTNewsPlus Therapeutics jumps 17% on manufacturing deal for Rhenium-186 NanoLiposomeN/A
2021-08-19 12:24 ESTNewsPlus Therapeutics reports encouraging 186RNL data in leptomeningeal metastasesN/A
2021-07-27 15:05 ESTNewsPlus Therapeutics inks deal to strengthens RNL supply chain; shares up 5%N/A
2021-07-23 05:16 ESTNewsPlus Therapeutics jumps 11% on treatment of first patient in latest cohort of ReSPECT-GBM trialN/A
2021-07-23 05:15 ESTNewsPlus Therapeutics EPS misses by $0.01N/A
2021-07-23 05:15 ESTNewsPlus Therapeutics, Inc. (PSTV) CEO Marc Hedrick on Q2 2021 Results - Earnings Call TranscriptN/A
2021-07-21 20:21 ESTNewsPlus Therapeutics to proceed with eighth cohort in ReSPECT glioblastoma trialN/A
2021-05-05 01:41 ESTNewsPlus Therapeutics shares rise 5% on Rhenium NanoLiposome development contractN/A
2021-04-23 19:20 ESTNewsPlus Therapeutics, Inc. (PSTV) CEO Marc Hedrick on Q1 2021 Results - Earnings Call TranscriptN/A
2021-04-22 21:01 ESTNewsPlus Therapeutics EPS beats by $0.03N/A
2021-03-24 23:43 ESTNewsPlus Therapeutics and Piramal Pharma ink master services agreementN/A
2021-03-23 08:34 ESTNewsPlus Therapeutics (PSTV) shares surge 48% on Rhenium NanoLiposome dealN/A
2021-03-01 12:13 ESTAnalyst RatingThe Analyst Target Price has increased from $6.56 to $6.75.Buy

About Plus Therapeutics, Inc (PSTV):

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium NanoLiposomes, a patented radiotherapy for patients with recurrent glioblastoma, which is in the Phase 1 dose-finding clinical trial. The company is also developing DocePLUS, a patented chemotherapy for patients with solid tumors that is in Phase 1 clinical trial; and DoxoPLUS, a generic chemotherapy for patients with ovarian cancer. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.

PSTV Quotes by TradingView

See Advanced Chart

General

  • Name Plus Therapeutics, Inc
  • Symbol PSTV
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 12
  • Last Split Factor1:50
  • Last Split Date2019-08-06
  • Fiscal Year EndDecember
  • IPO Date2000-11-16
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Web URLhttp://www.plustherapeutics.com
View More

Valuation

  • Trailing PE 0.43
  • Price/Sales (Trailing 12 Mt.) 43.26
  • Price/Book (Most Recent Quarter) 8.95
  • Enterprise Value Revenue 85.1
  • Enterprise Value EBITDA 30.6
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$1.43
  • Next Year EPS Estimate -$1.31
  • Next Quarter EPS Estimate -$0.37
  • Operating Margin -2905%
  • Return on Assets -31%
  • Return on Equity -393%
  • Revenue 303000
  • Earnings Per Share -$27.98
  • Revenue Per Share $0.07
  • Gross Profit -2397000
  • Quarterly Earnings Growth -100%
View More

Highlights

  • Market Capitalization 25.85 million
  • EBITDA -11121000
  • PE Ratio -0.57
  • Analyst Target Price $6.75
  • Book Value Per Share $0.06
View More

Share Statistics

  • Shares Outstanding 9.17 million
  • Shares Float 6.72 million
  • % Held by Insiders 620%
  • % Held by Institutions 11.04%
  • Shares Short 149878
  • Shares Short Prior Month 154300
  • Short Ratio 0.09
  • Short % of Float 2%
  • Short % of Shares Outstanding 2%
View More

Technicals

  • Beta 0.41
  • 52 Week High $4.1
  • 52 Week Low $1.01
  • 50 Day Moving Average 2.92
  • 200 Day Moving Average 2.51
View More

Dividends

  • Dividend Date 2019-08-06
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Plus Therapeutics, Inc (PSTV) Dividend Calendar:

PSTV's last dividend payment was made to shareholders on August 6, 2019.

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Plus Therapeutics, Inc (PSTV) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-02-22$N/A-$0.73-$0.40-84.81%
2020-09-302020-10-22$N/A-$0.39-$0.5529.09%
2020-06-302020-08-10$N/A-$0.45-$0.7540%
2020-03-312020-05-14$118000-$0.28-$0.7562.67%
2019-12-312020-03-30$N/A$14.48-$0.662293.94%
2019-09-302019-11-14$4.77 million-$0.03-$5.8599.49%
2019-06-302019-08-15$302000-$20.67-$10.00-106.7%
2019-03-312019-05-14$1.44 million-$9.00-$9.757.69%
2018-12-312019-03-29$2.14 million-$8.00-$14.6745.45%
2018-09-302018-11-14$1.31 million-$27.50-$12.00-129.17%
2018-06-302018-08-14$1.56 million-$29.50-$23.80-23.95%
2018-03-312018-05-10-$35.00-$28.00-25%
2017-12-312018-03-08-$100.00-$42.50-135.29%
2017-09-302017-11-09-$70.00-$78.3310.64%
2017-06-302017-08-10-$95.00-$105.009.52%
2017-03-312017-05-11-$165.00-$145.00-13.79%
2016-12-312017-03-23-$120.00-$115.00-4.35%
2016-09-302016-11-09$2.61 million-$130.00-$120.00-8.33%
2016-06-302016-08-04$2.83 million-$215.00-$195.00-10.26%
2016-03-312016-05-10$2.92 million-$225.00-$250.0010%
2015-12-312016-03-03-$150.00-$300.0050%
2015-09-302015-11-05$2.48 million-$0.60-$0.8226.83%
2015-06-302015-08-06$3.46 million-$0.90-$0.40-125%
2015-03-312015-05-11$2.35 million-$1.05-$1.01-3.96%
2014-12-312015-03-12-$1.20-$1.200%
2014-09-302014-11-06$1.1 million-$1.80-$1.05-71.43%
2014-06-302014-08-11$1.29 million-$1,125.00-$945.00-19.05%
2014-03-312014-05-12$1.43 million-$1,050.00-$1,031.25-1.82%
2013-12-312014-03-12-$1,050.00-$870.00-20.69%
2013-09-302013-11-07-$1,050.00-$825.00-27.27%
2013-06-302013-08-08-$375.00-$956.2560.78%
2013-03-312013-05-09-$825.00-$1,125.0026.67%
2012-12-312013-03-07-$450.00-$1,162.5061.29%
2012-09-302012-11-08-$1,425.00-$1,150.00-23.91%
2012-06-302012-08-08-$975.00-$1,050.007.14%
2012-03-312012-05-09-$1,200.00-$1,200.000%
2011-12-312012-03-08-$900.00-$1,050.0014.29%
2011-09-302011-11-03-$1,125.00-$1,150.002.17%
2011-06-302011-08-09-$750.00-$1,150.0034.78%
2011-03-312011-05-05-$1,725.00-$1,181.25-46.03%
2010-12-312011-03-10-$1,350.00-$1,256.25-7.46%
2010-09-302010-11-04-$1,725.00-$1,152.00-49.74%
2010-06-302010-08-07-$900.00-$862.50-4.35%
2010-03-312010-05-06-$450.00-$1,162.5061.29%
2009-12-312010-03-12-$1,800.00-$1,189.50-51.32%
2009-09-302009-11-09-$1,350.00-$1,146.00-17.8%
2009-06-302009-08-10-$150.00-$1,140.0086.84%
2009-03-312009-05-11-$1,500.00-$1,375.00-9.09%
2008-12-312009-03-06-$1,650.00-$2,025.0018.52%
2008-09-302008-11-10-$1,800.00-$1,980.009.09%
2008-06-302008-08-08-$2,475.00-$2,235.00-10.74%
2008-03-312008-05-09-$2,550.00-$2,715.006.08%
2007-12-312008-03-12-$3,300.00-$2,637.50-25.12%
2007-09-302007-11-12-$1,650.00-$2,700.0038.89%
2007-06-302007-08-14-$1,275.00-$3,000.0057.5%
2007-03-312007-05-11-$3,240.63
2006-12-312007-03-30-$750.00-$2,325.0067.74%
2006-09-302006-11-15-$3,951.23
2006-06-302006-08-14-$3,517.69
2006-03-312006-05-15-$3,624.68
2005-12-312006-03-30-$7,200.18
2005-09-302005-11-14-$1,130.69
2005-06-302005-08-15-$2,795.13
2005-03-312005-05-12-$2,433.17
2004-09-302004-11-02$2,325.57
2004-06-302004-08-16-$2,052.83
2004-03-312004-05-12$758.45
2003-12-312004-03-30-$590.02
2003-09-302003-11-03-$1,437.36

Plus Therapeutics, Inc (PSTV) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Plus Therapeutics, Inc (PSTV) Chart:

Plus Therapeutics, Inc (PSTV) News:

Below you will find a list of latest news for Plus Therapeutics, Inc (PSTV) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Plus Therapeutics, Inc (PSTV) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

Latest PSTV Trades:

Date Shares Price
Jun 13, 2022 2:28 PM EST10$0.591
Jun 13, 2022 7:59 PM EST200$0.6125
Jun 13, 2022 7:59 PM EST77$0.6125
Jun 13, 2022 7:59 PM EST277$0.6125
Jun 13, 2022 7:59 PM EST266$0.6125

Plus Therapeutics, Inc (PSTV) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-07-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1095981/000120919120039563/0001209191-20-039563-index.htm
2018-10-04UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1095981/000000000018031266/0000000000-18-031266-index.htm
2019-02-08UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1095981/000000000019001534/0000000000-19-001534-index.htm
2020-01-023Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1095981/000089924320000160/0000899243-20-000160-index.htm
2019-10-03SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1095981/000091957419006196/0000919574-19-006196-index.htm
2018-07-09POS AMPost-Effective amendments for registration statementhttps://www.sec.gov/Archives/edgar/data/1095981/000095012318006631/0000950123-18-006631-index.htm
2018-07-17S-1MEFRegistration adding securities to prior Form S-1 registration [Rule 462(b)]https://www.sec.gov/Archives/edgar/data/1095981/000095012318006834/0000950123-18-006834-index.htm
2018-09-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1095981/000095012318009531/0000950123-18-009531-index.htm
2020-05-14SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1095981/000101905620000342/0001019056-20-000342-index.htm
2020-05-22DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1095981/000109598120000002/0001095981-20-000002-index.htm
2018-08-28SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1095981/000114036118037106/0001140361-18-037106-index.htm
2018-06-12FWPFiling under Securities Act Rules 163/433 of free writing prospectuseshttps://www.sec.gov/Archives/edgar/data/1095981/000119312518190060/0001193125-18-190060-index.htm
2019-08-26SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1095981/000119312519229286/0001193125-19-229286-index.htm
2019-09-27SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1095981/000119312519256886/0001193125-19-256886-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1095981/000119312520038562/0001193125-20-038562-index.htm
2020-10-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1095981/000119312520275474/0001193125-20-275474-index.htm
2020-10-23424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1095981/000119312520275581/0001193125-20-275581-index.htm
2020-10-29S-1General form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1095981/000119312520281074/0001193125-20-281074-index.htm
2020-11-06424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1095981/000119312520288035/0001193125-20-288035-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1095981/000119380520000213/0001193805-20-000213-index.htm
2018-07-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1095981/000120919118044206/0001209191-18-044206-index.htm
2018-07-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1095981/000120919118044207/0001209191-18-044207-index.htm
2018-07-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1095981/000120919118044208/0001209191-18-044208-index.htm
2020-01-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1095981/000120919120004536/0001209191-20-004536-index.htm
2020-02-103Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1095981/000120919120008110/0001209191-20-008110-index.htm
2020-02-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1095981/000120919120008129/0001209191-20-008129-index.htm
2020-02-143Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1095981/000120919120009465/0001209191-20-009465-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1095981/000120919120009471/0001209191-20-009471-index.htm
2020-04-023Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1095981/000120919120022562/0001209191-20-022562-index.htm
2020-04-023Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1095981/000120919120022565/0001209191-20-022565-index.htm
2020-06-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1095981/000120919120038639/0001209191-20-038639-index.htm
2020-06-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1095981/000120919120039316/0001209191-20-039316-index.htm
2020-06-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1095981/000120919120039319/0001209191-20-039319-index.htm
2020-06-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1095981/000120919120039322/0001209191-20-039322-index.htm
2020-06-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1095981/000120919120039325/0001209191-20-039325-index.htm
2020-07-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1095981/000120919120039563/0001209191-20-039563-index.htm
2020-08-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1095981/000120919120046503/0001209191-20-046503-index.htm
2020-08-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1095981/000120919120046504/0001209191-20-046504-index.htm
2020-08-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1095981/000120919120046715/0001209191-20-046715-index.htm
2020-08-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1095981/000120919120048319/0001209191-20-048319-index.htm
2019-10-07SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1095981/000121390019019831/0001213900-19-019831-index.htm
2020-02-11SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1095981/000121390020003200/0001213900-20-003200-index.htm
2018-12-1725-NSENotification filed by national security exchange to report the removal from listing and registration of matured, redeemed or rethttps://www.sec.gov/Archives/edgar/data/1095981/000135445718000527/0001354457-18-000527-index.htm
2020-05-2625-NSENotification filed by national security exchange to report the removal from listing and registration of matured, redeemed or rethttps://www.sec.gov/Archives/edgar/data/1095981/000135445720000203/0001354457-20-000203-index.htm
2020-02-07SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1095981/000139382520000079/0001393825-20-000079-index.htm
2018-06-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1095981/000156459018015485/0001564590-18-015485-index.htm
2018-06-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1095981/000156459018015853/0001564590-18-015853-index.htm
2018-06-21CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1095981/000156459018015950/0001564590-18-015950-index.htm
2018-06-25424B4Prospectus [Rule 424(b)(4)]https://www.sec.gov/Archives/edgar/data/1095981/000156459018016071/0001564590-18-016071-index.htm
2018-07-13424B4Prospectus [Rule 424(b)(4)]https://www.sec.gov/Archives/edgar/data/1095981/000156459018016821/0001564590-18-016821-index.htm
2018-07-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1095981/000156459018016837/0001564590-18-016837-index.htm
2018-07-17424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1095981/000156459018016921/0001564590-18-016921-index.htm
2018-07-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1095981/000156459018017443/0001564590-18-017443-index.htm
2018-08-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1095981/000156459018021726/0001564590-18-021726-index.htm
2018-08-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1095981/000156459018021735/0001564590-18-021735-index.htm
2018-08-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1095981/000156459018022545/0001564590-18-022545-index.htm
2018-09-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1095981/000156459018022585/0001564590-18-022585-index.htm
2018-09-21S-1General form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1095981/000156459018023473/0001564590-18-023473-index.htm
2018-10-03CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1095981/000156459018023893/0001564590-18-023893-index.htm
2018-10-05424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1095981/000156459018024023/0001564590-18-024023-index.htm
2018-11-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1095981/000156459018029581/0001564590-18-029581-index.htm
2018-11-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1095981/000156459018029586/0001564590-18-029586-index.htm
2019-01-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1095981/000156459019000009/0001564590-19-000009-index.htm
2019-02-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1095981/000156459019001693/0001564590-19-001693-index.htm
2019-02-01S-1General form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1095981/000156459019001699/0001564590-19-001699-index.htm
2019-02-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1095981/000156459019002926/0001564590-19-002926-index.htm
2019-02-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1095981/000156459019004685/0001564590-19-004685-index.htm
2019-03-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1095981/000156459019006148/0001564590-19-006148-index.htm
2019-03-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1095981/000156459019008322/0001564590-19-008322-index.htm
2019-03-2910-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1095981/000156459019010018/0001564590-19-010018-index.htm
2019-04-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1095981/000156459019010318/0001564590-19-010318-index.htm
2019-04-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1095981/000156459019010321/0001564590-19-010321-index.htm
2019-04-05PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1095981/000156459019010945/0001564590-19-010945-index.htm
2019-04-19DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1095981/000156459019012053/0001564590-19-012053-index.htm
2019-04-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1095981/000156459019012357/0001564590-19-012357-index.htm
2019-04-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1095981/000156459019013984/0001564590-19-013984-index.htm
2019-05-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1095981/000156459019019177/0001564590-19-019177-index.htm
2019-05-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1095981/000156459019019181/0001564590-19-019181-index.htm
2019-05-30SDhttps://www.sec.gov/Archives/edgar/data/1095981/000156459019020930/0001564590-19-020930-index.htm
2019-05-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1095981/000156459019020939/0001564590-19-020939-index.htm
2019-06-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1095981/000156459019022519/0001564590-19-022519-index.htm
2019-06-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1095981/000156459019022821/0001564590-19-022821-index.htm
2019-06-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1095981/000156459019023871/0001564590-19-023871-index.htm
2019-07-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1095981/000156459019024261/0001564590-19-024261-index.htm
2019-07-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1095981/000156459019024571/0001564590-19-024571-index.htm
2019-07-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1095981/000156459019024844/0001564590-19-024844-index.htm
2019-07-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1095981/000156459019025075/0001564590-19-025075-index.htm
2019-07-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1095981/000156459019025505/0001564590-19-025505-index.htm
2019-07-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1095981/000156459019026454/0001564590-19-026454-index.htm
2019-08-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1095981/000156459019028357/0001564590-19-028357-index.htm
2019-08-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1095981/000156459019028996/0001564590-19-028996-index.htm
2019-08-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1095981/000156459019031278/0001564590-19-031278-index.htm
2019-08-14NT 10-QNotification of inability to timely file Form 10-Q or 10-QSBhttps://www.sec.gov/Archives/edgar/data/1095981/000156459019032183/0001564590-19-032183-index.htm
2019-08-1510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1095981/000156459019032349/0001564590-19-032349-index.htm
2019-08-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1095981/000156459019032689/0001564590-19-032689-index.htm
2019-09-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1095981/000156459019034402/0001564590-19-034402-index.htm
2019-09-10S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1095981/000156459019034406/0001564590-19-034406-index.htm
2019-09-16S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1095981/000156459019034798/0001564590-19-034798-index.htm
2019-09-16FWPFiling under Securities Act Rules 163/433 of free writing prospectuseshttps://www.sec.gov/Archives/edgar/data/1095981/000156459019034805/0001564590-19-034805-index.htm
2019-09-19CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1095981/000156459019035067/0001564590-19-035067-index.htm
2019-09-20CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1095981/000156459019035151/0001564590-19-035151-index.htm
2019-09-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1095981/000156459019035159/0001564590-19-035159-index.htm
2019-09-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1095981/000156459019035222/0001564590-19-035222-index.htm
2019-09-24424B4Prospectus [Rule 424(b)(4)]https://www.sec.gov/Archives/edgar/data/1095981/000156459019035317/0001564590-19-035317-index.htm
2019-10-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1095981/000156459019036889/0001564590-19-036889-index.htm
2019-11-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1095981/000156459019041987/0001564590-19-041987-index.htm
2019-11-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1095981/000156459019043516/0001564590-19-043516-index.htm
2019-11-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1095981/000156459019044603/0001564590-19-044603-index.htm
2019-12-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1095981/000156459019046259/0001564590-19-046259-index.htm
2019-12-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1095981/000156459019046396/0001564590-19-046396-index.htm
2020-01-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1095981/000156459020000150/0001564590-20-000150-index.htm
2020-02-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1095981/000156459020003735/0001564590-20-003735-index.htm
2020-03-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1095981/000156459020010228/0001564590-20-010228-index.htm
2020-03-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1095981/000156459020013839/0001564590-20-013839-index.htm
2020-03-3010-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1095981/000156459020014165/0001564590-20-014165-index.htm
2020-03-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1095981/000156459020014175/0001564590-20-014175-index.htm
2020-04-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1095981/000156459020018034/0001564590-20-018034-index.htm
2020-04-2910-K/AAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1095981/000156459020019787/0001564590-20-019787-index.htm
2020-05-01PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1095981/000156459020020524/0001564590-20-020524-index.htm
2020-05-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1095981/000156459020023811/0001564590-20-023811-index.htm
2020-05-13DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1095981/000156459020024840/0001564590-20-024840-index.htm
2020-05-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1095981/000156459020025453/0001564590-20-025453-index.htm
2020-05-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1095981/000156459020025461/0001564590-20-025461-index.htm
2020-06-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1095981/000156459020029008/0001564590-20-029008-index.htm
2020-06-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1095981/000156459020029658/0001564590-20-029658-index.htm
2020-06-30S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1095981/000156459020031140/0001564590-20-031140-index.htm
2020-08-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1095981/000156459020036123/0001564590-20-036123-index.htm
2020-08-1010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1095981/000156459020038551/0001564590-20-038551-index.htm
2020-08-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1095981/000156459020038560/0001564590-20-038560-index.htm
2020-09-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1095981/000156459020043477/0001564590-20-043477-index.htm
2020-10-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1095981/000156459020045822/0001564590-20-045822-index.htm
2020-10-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1095981/000156459020045846/0001564590-20-045846-index.htm
2020-10-09S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1095981/000156459020046208/0001564590-20-046208-index.htm
2020-10-2210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1095981/000156459020047266/0001564590-20-047266-index.htm
2020-10-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1095981/000156459020047276/0001564590-20-047276-index.htm
2018-06-22EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1095981/999999999518001600/9999999995-18-001600-index.htm
2018-07-12EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1095981/999999999518001772/9999999995-18-001772-index.htm
2018-10-05EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1095981/999999999518002559/9999999995-18-002559-index.htm
2019-09-23EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1095981/999999999519002148/9999999995-19-002148-index.htm
2020-10-19EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1095981/999999999520002910/9999999995-20-002910-index.htm
2020-11-05EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1095981/999999999520003092/9999999995-20-003092-index.htm

Plus Therapeutics, Inc (PSTV) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Plus Therapeutics, Inc (PSTV). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 620%
Institutional Ownership: 1104%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2020-08-12Greg PetersenDirectorBuy10,000.002.5225,200.0010,000.00https://www.sec.gov/Archives/edgar/data/1095981/000120919120046504/0001209191-20-046504-index.htm
2020-08-13Greg PetersenDirectorBuy10,000.002.8028,000.0020,000.00https://www.sec.gov/Archives/edgar/data/1095981/000120919120046715/0001209191-20-046715-index.htm
2020-08-25Robert P LenkDirectorBuy3,000.002.497,464.903,000.00https://www.sec.gov/Archives/edgar/data/1095981/000120919120048319/0001209191-20-048319-index.htm
2020-06-22MARC H HEDRICKChief Executive OfficerBuy5,000.002.1010,500.005,167.00https://www.sec.gov/Archives/edgar/data/1095981/000120919120038639/0001209191-20-038639-index.htm
2020-08-12MARC H HEDRICKChief Executive OfficerBuy4,000.002.5810,318.409,167.00https://www.sec.gov/Archives/edgar/data/1095981/000120919120046503/0001209191-20-046503-index.htm